Milestone Pharmaceuticals Refreshes Board of Directors
July 15, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 ...
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
June 12, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
May 31, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies...
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
May 29, 2024 07:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
May 22, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
May 13, 2024 07:15 ET
|
Milestone Pharmaceuticals Inc.
– NDA for etripamil in PSVT resubmitted in 1Q 2024– Cash resources as of March 31, 2024 expected to fund operations into 2026– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR...
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
May 02, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
April 17, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
April 08, 2024 11:36 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
April 03, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...